Beyond the Legacy: How Reed Jobs is Reshaping Oncology Venture Capital
Reed Jobs possesses an infectious energy-he is quick-witted, refreshingly self-aware, and speaks with the rapid-fire enthusiasm of someone deeply immersed in his craft. While he is inevitably linked to his father, Steve Jobs, he navigates that association with a grounded, unpretentious ease. When asked during a recent video interview if he was utilizing a MacBook, he responded with a dry, knowing humor: “Are you kidding?”
However, the true focus of his professional life is Yosemite, the oncology-centric venture firm he established in 2023. His mission is ambitious: to transform early-stage academic research into viable biotech enterprises by blending philanthropic funding with traditional venture capital. As the intersection of artificial intelligence and drug discovery accelerates, Jobs believes the window of opportunity for radical innovation in cancer treatment is wider than ever.
The Yosemite Strategy: Building from the Ground Up
Yosemite’s approach is distinct in the crowded venture landscape. Rather than waiting for established pharmaceutical companies to license breakthroughs, the firm actively incubates its own startups. By leveraging a hybrid model-using no-strings-attached philanthropic grants to de-risk nascent university research-Jobs is able to nurture high-potential ideas before they are ready for traditional equity investment.
The firm’s portfolio already boasts significant milestones. Notable examples include:
- Azalea: Emerging from Jennifer Doudna’s prestigious lab, this company has successfully transitioned into clinical trials.
- Quarry: Developed in collaboration with serial entrepreneur Craig Crews, this firm utilizes “induced proximity.” Instead of merely blocking a disease-causing protein, the drug physically maneuvers the protein toward the cell’s internal waste-disposal system for destruction.
A New Era for Biotech Investment
Since Yosemite’s inception, the biotech sector has undergone a dramatic shift. Following the post-pandemic market correction, the industry is now entering a period of intense activity. With a team of 17, Jobs is capitalizing on a unique market phenomenon: a massive “patent cliff” where several blockbuster drugs are losing exclusivity simultaneously. This creates a vacuum that major pharmaceutical companies are eager to fill through acquisitions, providing a clear exit path for innovative startups.
Furthermore, AI has evolved from a theoretical curiosity into a core pillar of Yosemite’s operational strategy. By integrating machine learning into clinical trial design and molecular discovery, the firm is significantly reducing the time and cost associated with bringing new therapies to market.
Q&A: Inside the Yosemite Model
TC: With your second fund targeting $350 million, how would you describe the current momentum at Yosemite?
RJ: We are in a phase of hyper-activity. We’ve secured strong partnerships and seen incredible traction. Our model is unique because we focus exclusively on oncology-which represents roughly 40% of the biotech sector-and we prioritize internal company creation. We don’t believe the next generation of cancer cures is just sitting on a shelf in a pharma lab; we believe in creating them from the ground up using cutting-edge knowledge. Our philanthropic arm is crucial here; it allows us to support “gentle” ideas in university labs without the pressure of immediate equity returns. In our first fund, two of our 20 companies were born directly from these grants.
<
The Biotech Renaissance: Capital, Policy, and the AI Revolution
The biotechnology sector is currently experiencing a period of intense activity, fueled by the substantial cash reserves companies accumulated during the pandemic. This financial cushion has triggered a wave of high-stakes mergers and acquisitions over the past several months. Notable examples include Eli Lilly’s $7 billion acquisition of Kelonia, signaling a robust appetite for innovation.
The clinical impact of this investment is becoming increasingly tangible. A prime example is the progress made by Revolution Medicines in targeting KRAS-a gene mutation long considered “undruggable” in pancreatic cancer. Recent breakthroughs have effectively doubled survival rates for patients with the most common form of the disease, extending life expectancy from 12 to 24 months.
## The Battle for NIH Funding: A Bipartisan Priority
Despite the sector’s growth, federal funding remains a point of contention. Last year, the industry faced an unprecedented proposal to slash the National Institutes of Health (NIH) budget by 40%. To put this in perspective, the most severe historical cut occurred in 2009, when a mere 1% reduction led to the loss of 7,000 scientific positions.
Fortunately, the proposal was met with fierce, bipartisan resistance in Congress. While the administration has since proposed a 12% reduction, it remains an outlier in terms of scale. Given that NIH funding enjoys over 90% public approval, these cuts are unlikely to gain traction. In fact, many experts argue that the U.S. should be increasing investment to $100 billion annually. When adjusted for inflation, NIH funding has remained stagnant for a decade, effectively representing a decline in real-world research capacity.
## Transforming Healthcare Delivery Through AI
While other sectors have digitized rapidly, hospitals remain surprisingly reliant on antiquated technology, with fax machines and legacy storage systems still in common use. Artificial Intelligence offers a path toward modernization, particularly in high-cost areas like 24/7 triage call centers, radiology, and pathology.
However, the most significant opportunity for AI lies in clinical trials, which currently represent the most expensive and time-consuming phase of drug development. A typical Phase 3 oncology trial requires an investment of roughly $260 million, with a success rate of only 33%. Much of this cost is tied to patient recruitment. By utilizing “synthetic control arms”-computer-generated models derived from existing patient data-researchers can potentially halve the number of participants needed for a trial. This approach not only accelerates the timeline but is also gaining support from the FDA.
## Beyond the Hype: AI in Drug Discovery
AI is proving to be a powerful tool for democratizing scientific research and automating labor-intensive processes. Its primary value lies in speed and reproducibility.
More importantly, AI is expanding the “druggable” portion of the human genome. Historically, scientists could only target about 15% of the genome because protein-to-protein interactions were chemically elusive. AI has changed this landscape by identifying “cryptic pockets” on proteins that were previously thought to be smooth, featureless surfaces.
Consider the “Death Star” protein, KRAS. For decades, it was considered impossible to target. While Amgen’s Lumakras was a breakthrough for one specific mutation, AI is now enabling researchers to identify and target a much broader range of variants, opening doors to treatments that were previously unimaginable.
## The Next Frontier: Targeting p53
The “holy grail” of oncology remains the p53 tumor suppressor gene. It is the most frequently deactivated gene in human cancers, making it a primary target for current research.
The biological inspiration for this work is fascinating: elephants, which rarely develop cancer, possess dozens of copies of the p53 gene, whereas humans rely on a single, vulnerable copy. By developing multiple
Revolutionizing Oncology: Insights from Yosemite’s Investment Frontier
The landscape of cancer research is shifting from broad-spectrum treatments to precision interventions that target the fundamental “Achilles’ heels” of malignancy. At the heart of this evolution is the p53 gene-a critical tumor suppressor that, when mutated, allows cancer to thrive. While traditional therapies have struggled to address these mutations, new breakthroughs are focusing on reactivating or neutralizing these specific markers across all mutation types, a feat previously considered impossible.
Epigenetic Editing: The Future of Viral and Chronic Disease
Tune Therapeutics stands at the forefront of this movement, pioneering epigenetic editing. Rather than altering the underlying DNA sequence, this technology acts as a biological dimmer switch. By adding or removing methyl groups-chemical tags that regulate gene expression-scientists can effectively silence harmful genes.
This mechanism is particularly promising for Hepatitis B, a condition affecting over 250 million people globally and a leading cause of liver cancer. By mimicking the body’s natural defense-where roughly 1% of patients spontaneously silence the virus-Tune Therapeutics aims to “turn off” the viral threat. This process is analogous to how the body naturally manages aging; for instance, the graying of hair occurs when melanin production is downregulated via methylation, even though the genetic blueprint for hair color remains intact.
Non-Invasive Innovation: The Rise of Histotripsy
While Yosemite typically focuses on drug development, Histosonics represents a strategic departure into medical devices. Their technology utilizes histotripsy, a non-invasive method for tumor destruction. By generating and collapsing microscopic air pockets within a targeted area-a process akin to high-precision ultrasound-the device can physically dismantle tumor tissue without the need for surgery. Given that pancreatic cancer frequently metastasizes to the liver, this technology offers a dual-threat solution for some of the most aggressive oncology cases.
Navigating the Biotech Investment Landscape
With a portfolio nearing 25 companies, Yosemite operates on a milestone-based investment model. In the high-stakes world of early-stage biotech, scientific failure is an inherent risk. When experiments fail to meet rigorous benchmarks, the firm pivots, viewing these outcomes as a necessary part of the innovation cycle.
For founders navigating the complex relationship with “Big Pharma,” the advice is clear: treat partnerships as a moving target. Corporate priorities are volatile; for example, the post-pandemic shift saw giants like Pfizer exit the infectious disease space entirely. Founders must remain agile, ensuring their strategic partners are still actively invested in their specific therapeutic area.
The Art of the Pitch: Why Narrative Drives Science
A common misconception in biotech is that the science speaks for itself. In reality, storytelling is a critical competency. Yosemite emphasizes a clear division of labor: the academic founder serves as the scientific visionary, while a professionalized CEO manages the narrative and capital acquisition. A brilliant discovery can easily fail if the leadership cannot articulate its value to investors.
The “GLP-1 Effect” and the Future of Disease Prevention
The industry is currently witnessing a massive paradigm shift driven by the success of GLP-1 agonists, which have propelled companies like Eli Lilly to trillion-dollar valuations. Beyond their primary use for weight management, these drugs are showing potential in mitigating neurodegenerative diseases and various cancers.
This is significant because obesity, alongside smoking, remains one of the few “pan-disease” risk factors that exacerbate nearly every major health condition. This realization has injected fresh capital and ambition into research areas that were previously considered stagnant, reigniting interest in “undruggable” targets like KRAS, Myc, and beta-catenin.
For innovators looking to partner with Yosemite, the door remains open. The firm prioritizes the merit of the idea over the pedigree
The Frontier of Genetic Medicine: Why the “Unstoppable” Oncogenes Are Finally Vulnerable
For years, certain oncogenes-the genetic drivers behind aggressive cancers-were considered virtually untouchable, remaining stubbornly beyond the reach of modern medicine. However, recent breakthroughs suggest we are entering a new era. The pace of innovation at institutions like Yosemite is accelerating at a rate that defies previous expectations. This rapid evolution is a double-edged sword: it is as daunting as it is transformative, signaling that we are finally gaining the upper hand against diseases that were once deemed inevitable.
Deconstructing the Longevity Hype
The burgeoning longevity sector has captured the public imagination, and while I have a personal stake in extending my own healthspan, I believe the industry is currently suffering from a lack of cohesion. We are essentially in the “Wild West” phase of aging research. If you poll a room of experts, you will receive a fragmented map of the problem: a geneticist will point to telomere degradation, an immunologist will highlight the exhaustion of T-cells, and a metabolomicist will focus on cellular energy pathways. Unlike physics, which relies on a Grand Unified Theory, the science of aging remains a collection of disparate observations.
Why Aging Defies a “One-Size-Fits-All” Solution
The fundamental challenge is that aging is not a singular, monolithic process. Instead, it is a complex, systemic phenomenon where different cell types degrade at varying rates, influenced by a unique interplay of internal and external factors. Because your body’s biological clock ticks differently across your organs and tissues, the idea of a universal “longevity pill” or a standardized anti-aging protocol is likely misguided.
True progress in this field requires a shift toward hyper-personalized healthcare. Rather than chasing a singular cure, the future of medicine lies in optimizing individual biological systems. While the business world is eager to package longevity into a scalable, one-size-fits-all product, the reality is far more nuanced. We aren’t looking at a single “longevity problem” to solve; we are looking at a lifetime of biological maintenance that must be tailored to the individual.
Note: This article contains affiliate links. If you choose to make a purchase through these connections, we may receive a modest commission. Please be assured that this does not influence our editorial integrity or the objectivity of our reporting.
